Abstract 1629P
Background
The management of pancreatic adenocarcinoma continues to be challenging. Surgical resection is the only modality for a cure, with an overall survival rate of 10–20% at 5 years. However, only 20% of the patients are surgical candidates because of locally advanced disease or systemic stage at presentation.
Methods
A phase II clinical trial was carried out on 50 patients with previously untreated locally advanced, surgically unresectable pancreatic adenocarcinoma. Patients had ECOG PS 0 or 1 and adequate hematologic, renal, and hepatic function. They arranged to receive 3 cycles of modified FOLFIRINOX prior to CCRT, with losartan taken orally every day followed by chemoradiotherapy.
Results
Response after completion CCRT was assessed. 6% of patients achieved complete response. 38% of the patients had a partial response, while twenty-four patients (48%) had stable disease and 8% had progressive disease. Of the 50 patients, thirteen (26%) underwent surgery, with R0 resection achieved in 6 of 13 patients. Median follow-up period was 20.25 months (range, 6.0-34.5). The median PFS was 12 months (95% CI, 9.647 – 14.353), while Median OS was 21 months (95% CI, (10.200–31.800). The patients who underwent resection had longer survival 24 months (95% CI, (16.363 – 27.637) compared to those who did not undergo resection; mean OS was 14 months (95% CI, (9.205 – 18.795)). (P=0.271). The patients who achieved CR after modified Folforinox-losartan had a longer median OS of 33 months (95% CI, 19.918 – 46.082) compared to patients who had PR and SD, each had median OS of 13 months (95% CI, 6.768 – 19.232), (11.718 – 14.282) respectively (P=0.040*). The patients who achieved CR after CCRT had longer OS (NR) compared to those who had PR, SD and PD. median OS was 24, 14 and 8 months, respectively (95% CI, 6.761 – 41.239), (11.022 – 16.978), and (95% CI, 4.080 – 11.920) (P=<0.001*). The patients who achieved CR after CCRT had longer PFS (NR) compared to those who had PR, SD and PD. Median PFS was 24 (95% CI, 13.191 – 34.809), 10(95% CI, 4.973 – 15.027) and 5 (95% CI,4.823-5.124) months, respectively (P=<0.001*).
Conclusions
Induction chemotherapy with modified-FOLFIRINOX-losartan, followed by CCRT improved patient outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Menoufia University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1701P - Cancer premium: Explaining differences in prices for cancer vs non-cancer drugs with efficacy and epidemiological endpoints in the US, Germany, and Switzerland
Presenter: Miquel Serra-Burriel
Session: Poster session 22
1702P - Real-world evidence contributions to European medicines agency’s safety and efficacy evaluations of oncology targeted therapies between 2018-2022
Presenter: Jeroen W. G. Derksen
Session: Poster session 22
1703P - Value of molecular targets and genome-targeted cancer therapies FDA-approved, 2015-2022
Presenter: Ariadna Tibau
Session: Poster session 22
1704P - Clinical benefit of cancer drugs approved by the US food and drug administration based on appropriateness of control arm and its change over time
Presenter: Molto Consolacion
Session: Poster session 22
1705P - Therapeutic value of first vs supplemental indications of drugs in the US and Europe (2011-2020): Retrospective cohort study
Presenter: Kerstin Vokinger
Session: Poster session 22